[Skip to Content]
[Skip to Content Landing]
March 1985

Treatment of Alopecia Areata

Author Affiliations

817 Douglas Rd Atlanta, GA 30342

Arch Dermatol. 1985;121(3):308-309. doi:10.1001/archderm.1985.01660030028011

To the Editor.—  Claudy and Gagnaire1 reported hair regrowth after treatment with systemic psoralens and UV-A (PUVA) in 64% (11 of 17) patients with alopecia areata (AA). Endocrine disorders were not reported, and the racial background (ie, white or nonwhite) of the seven women and 16 men, who were selected for treatment without apparent bias, was not identified. The reproductive history (fertility, surgical castration, genital abnormalities, gonadal autoantibodies) was not determined. Treatment results were presumed to be based on alleviation of a complex immunomodulatory mechanism involving the hair bulb. Topical PUVA therapy was recommended in our patients with AA due to the frequent association of AA with vitiligo. We believe that age, skin type, endocrine disease, and genetic predisposition to poliosis, AA, vitiligo, or endocrinopathy could influence the response to therapy.2-5In the study by Claudy and Gagnaire,1 the success of PUVA treatment was primarily segregated between

First Page Preview View Large
First page PDF preview
First page PDF preview